TB Multi-drug Resistant Clinical Trial
— Estudio EpiOfficial title:
Epidemiology of Multidrug-Resistant Tuberculosis in Peru
The purpose of this study is to better understand tuberculosis (TB) and the risk of infection with TB, in Peru. TB is a disease that is caused by bacteria and transmitted through droplets in the air that come from the lungs of an infected person. The risk of infection will be compared between two groups: household members, who live with people having TB that does not respond well to treatment and household members, who live with people having TB that responds well to treatment. Study participants will include 4,500 TB infected people and 22,500 of their household contacts. Study procedures include answering a questionnaire, TB skin tests, blood samples, and a chest x-ray. Individuals with symptoms indicating TB will be asked to provide sputum samples. Individuals with TB will be involved in the study for up to 48 months; household contacts will be involved in the study for 12 months. The knowledge gained from this study will be used to improve tuberculosis control.
Status | Active, not recruiting |
Enrollment | 18544 |
Est. completion date | September 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: TB index subjects - During the enrollment period, the participant is found to have characteristic acid-fast bacilli shown by the Ziehl-Neelsen stain on a smear of sputum indicating active disease due to M. tuberculosis. - Participant is at least 16 years old at the time of enrollment. - Participant lives in one of the study districts. - If age 18 years or older, participant provides informed consent to participate. If age 16 or 17 years, a guardian provides informed consent for minor to participate, and the minor also provides assent. Household members - Participant lives in the same household as an index subject at the time the index subject is enrolled in the study. - If eligible participant is age 18 years or older, participant provides informed consent to participate. If participant is younger than 18 years, a parent or guardian provides informed consent for minor to participate. If eligible participant is age 10-17 years, the minor also provides assent. Exclusion Criteria: - Apart from the age restriction (age 16 years and older) for the group of TB index subjects, no other exclusion criteria apply. - Previous diagnosis with TB disease will not be considered a reason for exclusion from the study. - Pregnant or breast-feeding women will be eligible to participate in the study. - Prior to beginning routine TB treatment, health center workers provide women with routine counseling about the use of contraceptive methods during TB treatment; this is not a study activity. - Subjects who live alone will be included in the study and will contribute to addressing the third and fourth study objectives. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Peru | Socios En Salud Sucursal Peru | Lima |
Lead Sponsor | Collaborator |
---|---|
Harvard University Faculty of Medicine | Brigham and Women's Hospital, Harvard School of Public Health, National Institute of Allergy and Infectious Diseases (NIAID), Socios En Salud Sucursal Peru |
Peru,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Relative risk of relapse and reinfection in index patients who are sick with drug-resistant M. tuberculosis strains compared to index patients sick with drug-sensitive strains. | 24-month period after completing TB drug therapy | No | |
Primary | Risk of TB infection among the household members | at months 6 and 12 after study enrollment | No | |
Secondary | Relative risk of specific DR mutations in index case across household contacts who acquire TB from strain matching the index case strain, vs. disease-free contacts; and cases whose contacts do/do not convert from negative to positive PPD skin test. | at months 6 and 12 after study enrollment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00866190 -
Dose Escalation Study of SQ109 in Healthy Adult Volunteers
|
Phase 1 |